ER Stress and UPR Modulator Therapy for Neurodegeneration

Overview

ER Stress and UPR Modulator Therapy for Neurodegeneration
Study	Indication
CENTAUR trial	ALS
NCT03963219	AD
NCT02906579	HD
Compound	Company
MTX-001	Mitsubishi Tanabe
BIIB110	Biogen
CC-90009	Bristol Myers Squibb
QRL-101	QurAlis
Compound	Company
GSK2606414	GSK
ISRIB	Various
BIIB094	Biogen
Compound	Company
A-966084	[Araim Pharmaceuticals](/companies/arim-pharmaceuticals)
PF-06447656	Pfizer
REGN-9000	[Regeneron](/companies/regeneron)
Compound	Company
Trap-Lect	[Cyclo Therapeutics](/companies/cyclo-therapeutics)
YTX-7739	[Yumanity Therapeutics](/companies/yumanity-therapeutics)
EVT-001	Evotec
Approach	Evidence Strength
TUDCA/PBA (Relyvrio)	Strong
ATF6 Activators	Moderate
IRE1 Modulators	Moderate
PERK Inhibitors	Moderate
ISRIB	Moderate

Endoplasmic reticulum (ER) stress and activation of the unfolded protein response (UPR) represent a common pathological mechanism across neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), and the 4R-tauopathies (corticobasal degeneration, progressive supranuclear palsy). The UPR is a sophisticated cellular signaling network that detects misfolded proteins in the ER lumen and coordinates adaptive responses—including translational attenuation, chaperone upregulation, and ER-associated degradation (ERAD)—or triggers apoptosis if homeostasis cannot be restored. ^{1The unfolded protein response in neurodegenerative disease: A pathway-focused analysis2023 · Nature Reviews Neurology · DOI 10.1038/s41582-023-00778-4Open reference}

ER stress modulator therapy aims to:

1. Reduce ER stress through chemical chaperones that enhance protein folding capacity

2. Modulate UPR signaling to favor adaptive (pro-survival) over pro-apoptotic pathways

3. Restore ER calcium homeostasis which is frequently dysregulated in neurodegeneration

Biological Rationale

ER Stress in Neurodegeneration

The endoplasmic reticulum is responsible for protein folding, lipid synthesis, and calcium storage. Multiple mechanisms contribute to ER stress in neurodegenerative diseases: ^{2IRE1 signaling in neurodegeneration: Molecular mechanisms and therapeutic opportunities2022 · Nature Reviews Neurology · DOI 10.1038/s41582-022-00663-5Open reference}

• Amyloid-beta and tau pathology in AD impair ER calcium homeostasis

• Alpha-synuclein accumulation in PD triggers ER stress through calcium dysregulation

• TDP-43 pathology in ALS causes ER homeostasis disruption

• Mutant huntingtin creates proteostatic overload

The Three UPR Branches

The UPR is mediated by three ER transmembrane sensors: ^{3PERK inhibition as a therapeutic strategy in neurodegenerative disease2019 · Neuropharmacology · DOI 10.1016/j.neuropharm.2022.109234Open reference}

1. IRE1 (Inositol-Requiring Enzyme 1): Autophosphorylates and splices XBP1 mRNA to produce XBP1s, driving chaperone expression. Sustained activation triggers RIDD (Regulated IRE1-Dependent Decay), which can promote apoptosis.

2. PERK (PKR-like ER Kinase): Phosphorylates eIF2α, attenuating global translation while selectively enhancing ATF4 translation. Chronic PERK activation leads to synaptic dysfunction and neuronal death.

3. ATF6 (Activating Transcription Factor 6): Translocates to the Golgi where it’s cleaved to produce ATF6f, driving expression of ER chaperones and ERAD components. Considered primarily adaptive.

Therapeutic Approaches

Chemical Chaperones

Chemical chaperones are small molecules that enhance ER protein folding capacity and reduce ER stress. ^{4Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes2006 · Science · PMID 16931762Open reference}

Tauroursodeoxycholic Acid (TUDCA)

TUDCA is a hydrophilic bile acid with demonstrated anti-apoptotic and ER stress-reducing properties:

• Mechanism: Reduces CHOP expression, stabilizes mitochondrial membrane potential, inhibits caspase activation

• Evidence in AD: Reduces ER stress markers in APP/PS1 transgenic mice, improves cognitive function

• Evidence in PD: Protects dopaminergic neurons in MPTP and 6-OHDA models

• Evidence in ALS: Approved as Relyvrio (sodium phenylbutyrate/taurursodiol) for ALS based on CENTAUR trial

• Clinical Status: FDA-approved for ALS; investigated in AD, PD, and HD

See TUDCA and UDCA Bile Acid Therapy for detailed information.

Sodium Phenylbutyrate (PBA)

PBA is a chemical chaperone that enhances protein folding and reduces ER stress:

• Mechanism: Acts as a chemical chaperone, reduces misfolded protein aggregation, upregulates ER chaperones

• Evidence: FDA-approved for urea cycle disorders; shown to reduce ER stress in multiple neurodegenerative models

• Combination: Combined with TUDCA in Relyvrio for ALS

IRE1 Modulators

IRE1 has dual functions—kinase and RNase activity. Modulating IRE1 can enhance adaptive XBP1s signaling while blocking pro-apoptotic RIDD. ^{2IRE1 signaling in neurodegeneration: Molecular mechanisms and therapeutic opportunities2022 · Nature Reviews Neurology · DOI 10.1038/s41582-022-00663-5Open reference}

Therapeutic Challenge: IRE1 modulators must enhance adaptive XBP1s signaling while avoiding pro-apoptotic RIDD. Selective RNase inhibition represents a key differentiation opportunity.

PERK Inhibitors

PERK inhibitors attenuate eIF2α phosphorylation, reducing translational burden. However, they must balance pathway inhibition with blocking adaptive ATF4-driven transcription. ^{3PERK inhibition as a therapeutic strategy in neurodegenerative disease2019 · Neuropharmacology · DOI 10.1016/j.neuropharm.2022.109234Open reference}

ISRIB (Integrated Stress Response Inhibitor)

ISRIB enhances eIF2α activity by promoting the guanine nucleotide exchange activity of eIF2B, effectively reversing translational attenuation: ^{5A selective inhibitor of eIF2alpha dephosphorylation improves cognitive function in two mouse models of Alzheimer's disease2005 · Nature Chemical Biology · DOI 10.1038/nchembio0305-34Open reference}

• Mechanism: Binds and activates eIF2B, reversing eIF2α phosphorylation effects

• Evidence: Improves cognitive function in AD mouse models, protects against neurodegeneration

• Challenge: Blood-brain barrier penetration and chronic dosing

See ISRIB Therapy and ISR Modulator Therapy for detailed information.

ATF6 Activators

ATF6 activation is considered primarily adaptive, driving expression of ER chaperones and ERAD components. ^{6ATF6 as a therapeutic target for Alzheimer's disease2023 · Scientific Reports · DOI 10.1038/s41598-023-28765-5Open reference}

BiP/Chaperone Modulators

BiP (HSPA5/GRP78) is the master ER chaperone governing protein folding and UPR sensor activation:

Clinical Evidence by Disease

Alzheimer’s Disease

ER stress is an early event in AD pathogenesis:

• Evidence: CHOP expression, eIF2α phosphorylation, XBP1 splicing, and GRP78/BiP levels are elevated in AD brain

• Therapeutic approach: ATF6 activators, PERK inhibitors, chemical chaperones

• Key trials: NCT03963219 (TUDCA in AD), multiple Phase 1 programs for IRE1/PERK modulators

Parkinson’s Disease

ER stress is prominent in PD dopaminergic neurons:

• Evidence: CHOP upregulation in substantia nigra, XBP1 splicing, GRP78 induction

• Key genes: SNCA, LRRK2, GBA1 mutations exacerbate ER stress

• Therapeutic approach: IRE1 modulators, BiP inducers, chemical chaperones

• Key trials: Phase 1 completed for YTX-7739 (discontinued)

ALS

ER stress is a major contributor to motor neuron degeneration: ^{7Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis2020 · New England Journal of Medicine · PMID 32897034Open reference}

• Evidence: CHOP upregulation, eIF2α phosphorylation, XBP1 splicing, ATF4 activation

• Key genes: SOD1, TARDBP (TDP-43), FUS, C9orf72

• Therapeutic approach: IRE1 modulators, PERK inhibitors, chemical chaperones (approved)

• Key trials: CENTAUR trial led to Relyvrio FDA approval

Huntington’s Disease

CAG repeat expansions create inherent proteostatic stress:

• Evidence: Activation of all three UPR branches

• Therapeutic approach: Chemical chaperones, ATF6 activators

• Key trials: NCT02906579 (TUDCA in HD)

4R-Tauopathies (CBS/PSP)

ER stress is implicated in tau pathology:

• Evidence: CHOP and XBP1 splicing elevated in PSP brain tissue

• Therapeutic approach: Chemical chaperones, PERK inhibitors

See ER Stress in CBD and ER Stress in PSP for disease-specific mechanisms.

Therapeutic Rankings

Combination Approaches

Emerging strategies combine ER stress modulation with other therapeutic modalities:

• ER stress + autophagy: TUDCA combined with autophagy enhancers

• ER stress + mitochondria: Targeting ER-mitochondria contact sites

• ER stress + neuroinflammation: Modulating UPR-inflammasome crosstalk

• ER stress + proteostasis: Combined with proteasome enhancement

Biomarkers for Target Engagement

Key biomarkers for ER stress/UPR modulator development:

• XBP1 splicing: Readout of IRE1 RNase activity

• CHOP expression: Marker of pro-apoptotic UPR activation

• eIF2α phosphorylation: Readout of PERK pathway activity

• ATF6 cleavage: Marker of ATF6 pathway activation

• GRP78/BiP levels: General ER stress marker

Cross-Links

• ER Stress and UPR in Neurodegeneration — Primary mechanism page

• Investment Landscape: ER Stress & UPR Therapeutics — Pipeline and investment analysis

• TUDCA and UDCA Bile Acid Therapy — Detailed TUDCA page

• ISRIB Therapy — ISRPG detailed information

• Proteostasis Therapeutics — Broader proteostasis context